The Duke-Margolis Center for Health Policy’s Real-World Evidence Collaborative is proud to have its white papers cited in a diverse number of publications. The following running list of citations is current as of September 2023.

**Table of Contents**

A Framework for Regulatory Use of Real-World Evidence  
Page 2

Characterizing RWD Quality and Relevancy for Regulatory Purposes  
Page 15

Determining Real-World Data’s Fitness for Use and the Role of Reliability  
Page 20

Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility  
Page 26

Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness  
Page 29

A Roadmap for Developing Study Endpoints in Real-World Settings  
Page 32

Point-of-Care Clinical Trials: Integrating Research and Care Delivery  
Page 34

Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Data Ecosystem  
Page 34
A Framework for Regulatory Use of Real-World Evidence
“The First White Paper”


De, Sugato, Leanne Larson, Kim Kelly, Beate Hanson, and Christina D. Mack. “Leveraging Real-World Evidence: A Paradigm Shift in Regulation.” *Journal of


Kerra Mercon, Nirosa Mahendraratnam, Joy Eckert, Christina Silcox, Morgan


Oksen, Dina, Patricia Prince, Emmanuelle Boutmy, Elizabeth M. Garry, Barbara Ellers-Lenz, Adina Estrin, Andreas John, Patrice Verpillat, and Nicolle M.


Robert S. Miller, Kristi Mitchell, Rachel Myslinski, and Josh Rising. “Health Information Technology (IT) and Patient Registries.” In *Tools and


Characterizing RWD Quality and Relevancy for Regulatory Purposes

“The Data Quality Paper”


Gressler, Laura Elisabeth, this link will open in a new window Link to external site, Danica Marinac-Dabic, Susan dosReis, Philip Goodney, this link will open in a new window Link to external site, C. Daniel Mullins, and Fadia Shaya. “Creation of Objective Performance Criteria among Medical Devices.” *BMJ*


Determining Real-World Data’s Fitness for Use and the Role of Reliability
“The Data Reliability Paper”


He, Weili, Yixin Fang, Hongwei Wang, and Ivan Chan. “Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management.” Statistics in Biopharmaceutical Research 15, no. 1 (January 2,


Klimek, Peter, Dejan Baltic, Martin Brunner, Alexander Degelsegger-Marquez,


Ryan J. Shaw, Mina Boazak, Victoria Tiase, Gloria Porter, Jedrek Wosik, Sarah Bumatay, LeAnn Michaels, Julie Stone, Deborah Cohen, and Rowena Dolor. “Integrating Patient-Generated Digital Health Data into Electronic Health Records in Ambulatory Care Settings: An Environmental Scan.” Agency for


Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility

“The Credibility Paper”


“Comparative Effectiveness of Tocilizumab vs Standard Care in Patients with Severe COVID-19–Related Pneumonia: A Retrospective Cohort Study Utilizing Registry Data as a Synthetic Control,” May 5, 2023. https://doi.org/10.21203/rs.3.rs-2866088/v1.


https://doi.org/10.1007/s43441-020-00131-5.


Nirosha Mahendraratnam, Joy Eckert, Kerra Mercon, Katherine Frank, Morgan Romine, Adam Kroetsch, Rachel Sherman, Gregory Daniel, and Mark


Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness
“The Totality of Evidence Paper”


Eskola, Sini Marika, Hubertus Gerardus Maria Leufkens, Andrew Bate, Marie Louise De Bruin, and Helga Gardarsdottir. “Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in


Nirosha Mahendraratnam, Kerra Mercon, Joy Eckert, Morgan Romine, Adam


A Roadmap for Developing Study Endpoints in Real-World Settings
“The RWE Endpoints Paper”


Point-of-Care Clinical Trials: Integrating Research and Care Delivery
“The POC Paper”

Bahls, Christine. “‘Record’ Gains in Bringing Research Closer to the Patient.” Applied Clinical Trials 31, no. 9 (September 2022): 19–22.

Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Evidence Ecosystem
“The SEO Paper”